Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.

PMID:
28818518
2.

Common Variable Immunodeficiency and Liver Involvement.

Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Eric Gershwin M, Leung PSC.

Clin Rev Allergy Immunol. 2017 Aug 7. doi: 10.1007/s12016-017-8638-z. [Epub ahead of print] Review.

PMID:
28785926
3.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK.

Gut. 2017 Aug 4. pii: gutjnl-2016-313598. doi: 10.1136/gutjnl-2016-313598. [Epub ahead of print]

PMID:
28779025
4.

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Henriksen EKK, Viken MK, Wittig M, Holm K, Folseraas T, Mucha S, Melum E, Hov JR, Lazaridis KN, Juran BD, Chazouillères O, Färkkilä M, Gotthardt DN, Invernizzi P, Carbone M, Hirschfield GM, Rushbrook SM, Goode E; UK-PSC Consortium, Ponsioen CY, Weersma RK, Eksteen B, Yimam KK, Gordon SC, Goldberg D, Yu L, Bowlus CL, Franke A, Lie BA, Karlsen TH.

HLA. 2017 Oct;90(4):228-233. doi: 10.1111/tan.13076. Epub 2017 Jul 11.

PMID:
28695657
5.

Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.

Tanaka T, Zhang W, Sun Y, Shuai Z, Chida AS, Kenny TP, Yang GX, Sanz I, Ansari A, Bowlus CL, Ippolito GC, Coppel RL, Okazaki K, He XS, Leung PSC, Gershwin ME.

Hepatology. 2017 Sep;66(3):885-895. doi: 10.1002/hep.29245. Epub 2017 Jul 20.

PMID:
28470667
6.

Geoepidemiology and changing mortality in primary biliary cholangitis.

Floreani A, Tanaka A, Bowlus C, Gershwin ME.

J Gastroenterol. 2017 Jun;52(6):655-662. doi: 10.1007/s00535-017-1333-2. Epub 2017 Apr 1. Review.

PMID:
28365879
7.

Human β-Defensin 2 in Primary Sclerosing Cholangitis.

Chang C, Lleo A, Kananurak A, Grizzi F, Tsuneyama K, Invernizzi P, Bevins CL, Bowlus CL.

Clin Transl Gastroenterol. 2017 Mar 16;8(3):e80. doi: 10.1038/ctg.2017.8.

8.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

9.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
10.

The evolution of natural history of primary sclerosing cholangitis.

Takakura WR, Tabibian JH, Bowlus CL.

Curr Opin Gastroenterol. 2017 Mar;33(2):71-77. doi: 10.1097/MOG.0000000000000333.

PMID:
28030370
11.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.

Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall HU, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M; UK-PSC Consortium; International IBD Genetics Consortium; International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA.

Nat Genet. 2017 Feb;49(2):269-273. doi: 10.1038/ng.3745. Epub 2016 Dec 19.

12.

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.

Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen MS Jr.

World J Gastroenterol. 2016 Oct 14;22(38):8584-8595.

13.

Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.

Bowlus CL, Kenney JT, Rice G, Navarro R.

J Manag Care Spec Pharm. 2016 Oct;22(10-a-s Suppl):S3-S15. Review.

14.

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.

Bowlus CL.

Hepat Med. 2016 Sep 1;8:89-95. doi: 10.2147/HMER.S91709. eCollection 2016. Review.

15.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group.

N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.

16.

The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.

Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X.

Clin Rev Allergy Immunol. 2017 Jun;52(3):424-435. doi: 10.1007/s12016-016-8583-2.

PMID:
27515672
17.

Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis.

Chak EW, Sarkar S, Bowlus C.

Dig Dis Sci. 2016 Oct;61(10):2776-2783. doi: 10.1007/s10620-016-4205-3. Epub 2016 May 27. Review.

PMID:
27234269
18.

Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice.

Yang GX, Sun Y, Tsuneyama K, Zhang W, Leung PS, He XS, Ansari AA, Bowlus C, Ridgway WM, Gershwin ME.

Clin Exp Immunol. 2016 Aug;185(2):154-64. doi: 10.1111/cei.12806. Epub 2016 Jun 6.

19.

Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).

Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME.

Autoimmun Rev. 2016 Aug;15(8):795-800. doi: 10.1016/j.autrev.2016.03.019. Epub 2016 Mar 24. Review.

PMID:
27019050
20.

Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M, Torzilli G, Rimassa L, Piscaglia F, He XS, Bowlus CL, Yang GX, Gershwin ME, Invernizzi P.

Clin Exp Immunol. 2016 Jul;185(1):61-71. doi: 10.1111/cei.12776. Epub 2016 May 17.

Supplemental Content

Loading ...
Support Center